In particular, anakinra, a human recombinant IL-1 antagonist, has been shown to significantly reduce the progression of choroidal neovascularization and ameliorated endothelial dysfunction in diabetic animal models [35, 70]. This evidence concerns the gene IL1B and endothelial dysfunction.